等待开盘 07-02 09:30:00 美东时间
0.000
0.00%
4D Molecular Therapeutics (4DMT) has secured a $200 million strategic credit facility with Hercules Capital to support its gene therapy pipeline, particularly the Phase 3 development of 4D-150 for wet AMD and DME. The company's CFO, Kristian Humer, highlighted the agreement's benefits, including enhanced financial flexibility and a diversified capital structure. Hercules Capital expressed confidence in 4DMT's innovative approach to genetic medici...
06-29 12:00
Beren Therapeutics Secures $300M In Combined Financing With Hercules Capital To Support Investments In Commercial Readiness Activities For Adrabetadex Ahead Of November 17 PDUFA Target Action Date
06-10 21:06
The $300m facility backed by top-tier lenders reflects strong conviction in Perk's vision to build a leading AI-native platform for travel and spend managementPerk enters its next phase of growth on the back of a 48%
06-03 19:19
Smart credit team Ares Mgmt bought discounted BDCs aggressively in Q1 2026. They're not guessing but expressing conviction in 17 positions.
05-25 01:33
Private credit bond spreads show smaller lenders priced at greater risk By Patturaja Murugaboopathy May 21 (Reuters) - Bond investors are assigning diverse risk premiums to U.S. private credit firms, with smaller lenders being priced at greater risk and hence wider spreads than larger funds, a Reut
05-21 22:04
Trinity Capital (Nasdaq: TRIN) on Tuesday said it priced an underwritten public offering of $300 million aggregate principal amount of 7.0% notes due 2031. The unsecured notes will mature on May 21, 2...
05-20 05:20
UBS analyst Vilas Abraham maintains Hercules Capital (NYSE:HTGC) with a Neutral and raises the price target from $15 to $15.5.
05-19 03:27
Hercules Capital, Inc. received a Hold rating and a $15.50 price target from UB...
05-18 21:37
U.S. RESEARCH ROUNDUP-Exxon Mobil, Northrop Grumman, Regeneron Pharmaceuticals May 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Exxon Mobil, Northrop Grumman and Regeneron Pharmaceuticals on Monday. HIGHLIGHTS * Ch
05-18 15:15
Viridian Therapeutics (VRDN) priced upsized concurrent public offerings totaling $350M in gross proceeds, including $225M of 1.75% convertible senior notes due 2032 and $125M of common stock. The conv...
05-07 13:36